Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

GlycoMimetics logo

About GlycoMimetics Stock (NASDAQ:GLYC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$27.47
52-Week Range
N/A
Volume
1.05 million shs
Average Volume
65,917 shs
Market Capitalization
$10.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

GlycoMimetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

GLYC MarketRank™: 

GlycoMimetics scored higher than 20% of companies evaluated by MarketBeat, and ranked 862nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about GlycoMimetics' valuation and earnings.
  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GlycoMimetics does not currently pay a dividend.

  • Dividend Growth

    GlycoMimetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • Search Interest

    1 people have searched for GLYC on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of GlycoMimetics is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GlycoMimetics' insider trading history.
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

Crescent Biopharma Inc.
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Headlines

GLYC Stock Analysis - Frequently Asked Questions

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($4.00) EPS for the quarter, beating analysts' consensus estimates of ($5.00) by $1.00.

Shares of GlycoMimetics reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/14/2025
Today
7/15/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLYC
CIK
1253689
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Net Margins
N/A
Pretax Margin
-397,340.00%
Return on Equity
-230.74%
Return on Assets
-177.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.92
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
64,532,000
Free Float
58,901,000
Market Cap
$10.00 million
Optionable
Optionable
Beta
1.62

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:GLYC) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners